The Bulletin
The Times


.

Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer

  • Written by PR Newswire
  • Becomes the 7th International Registrational Clinical Trial for Ivonescimab
  • Clinical Trial Site Activations in the United States Expected to Begin Q4 2026

HONG KONG, Oct. 21, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced that Summit Therapeutics Inc. (NASDAQ: SMMT), its global partner for ivonescimab, has entered into a clinical...

The Bulletin Magazine

Executive Recruitment for Education Leadership: What Schools Should Consider

Practical Guide to Roller Shutters for Safer, More Comfortable Homes

Why the Advertised Rate on a Bonus Saver Account Isn't What Most Savers Actually Earn

The Essential Bathroom Renovation Supplies Checklist Before You Start

Pull Up Stands: A Convenient Display Option for Events and Promotions

How Mining Hose Selection Can Improve Material Transfer Systems

Electric Sliding Door: What to Consider Before Choosing One

What Is Included in a Professional Roof Repair Service on the Gold Coast?

The Unglamorous Baby Buys That Save Australian Parents the Most Time

Cryptocurrency Trading in 2026_ Why Regulated Education Is the New Standard

How Mining Hose Routing Can Influence Wear and Transfer Efficiency

Cryotherapy in Melbourne: What Skin Lesions Can Be Treated with Targeted Cold Therapy?

hacklink zlibraryzlibraryz-librarySahabetviljo kasinot kirjautuminenbetoffice güncel girişzimpler kasinotbetoffice1xbetjojobetcasibomcasibomjojobettaraftarium24taraftariumkingroyalhacklink panelyks koçlukvsf watchesjojobet